A Note from Our CEO

Michel Vounatsos
Chief Executive Officer

It is a remarkable time to lead an organization at the forefront of breakthroughs in neuroscience. Our commitment to understanding the complexities of neurological disorders with few, if any, treatment options, builds upon Biogen’s legacy of translating innovative science into medicines that can help transform the lives of patients and those who care for them. To me, there is no greater challenge in medicine than finding treatments for these diseases. At Biogen, our mission is clear.

Building upon our heritage as the leader in developing therapies for multiple sclerosis, today we are working to find breakthroughs for some of the toughest challenges in medicine – including potential treatments for the millions of people suffering from debilitating diseases such as Alzheimer’s disease, Parkinson’s disease, stroke and neuropathic pain. The 2016 U.S. approval of SPINRAZA® – the first and only therapy for the treatment of the neurodegenerative disease spinal muscular atrophy (SMA) – represents one such breakthrough, and our team is working every day to ensure that children afflicted with this deadly disorder have access to this medicine.

To us, this is Science That Matters.

But Science That Matters goes beyond our therapies. It includes the rigor and commitment to improving patient health outcomes, building supportive communities, and inspiring future generations of scientists. To that end, I am proud to bring to you our 2016 Global Impact Report, highlighting many of the critical areas in which Biogen has continued to innovate, from our commitment to carbon neutrality and our pioneering science education programs to our ongoing efforts to promote diversity and gender equality in science and in the workplace.

2016 Report Highlights

Science That Matters for Patients

  • Biogen products treat 38% of MS patients worldwide
  • Ranked sixth on IDEA Pharma’s 2016 Product Innovation Index
  • Launched 1MSg®, a new MS campaign, to encourage MS patients to work with medical specialists and become even better informed
  • Created Together in SMA (spinal muscular atrophy), a disease education program to provide information about SMA and its symptoms
  • Received FDA approval of SPINRAZA (nusinersen), the first therapy approved to treat children and adults with SMA

Science That Matters for Society

  • Reduced operational carbon intensity by 70% since 2006
  • Engaged 75% of suppliers in climate change strategy
  • Reduced weight of packaging materials by 28.5 metric tons per year and decreased shipping costs by 30%
  • Screened 100% of all supply chain spending, including smaller, non-Tier 1 suppliers

Science That Matters for Communities

  • Nearly 90% of employees indicated they were proud to work for Biogen, exceeding the industry benchmark by 20 percentage points
  • 48% of director-level positions are held by women
  • Employee-matched gifts in the U.S. totaled $1.3 million in 2016
  • 3,000 employees in 25 countries supported 62 projects as part of 2016 Care Deeply Volunteer Day
  • 4,960 students participated in our Community Lab to learn more about science

Please send questions or feedback about the 2016 Global Impact Report to impact@biogen.com.